BlossomHill Therapeutics, Inc. (BLSM)

NASDAQ: BLSM · USD

$16.2

+0.43 (+2.8%)· Recorded snapshot

Market cap	514.6M
Net income (ttm)	-81.6M
EPS (ttm)	-$31.8
Shares out	31.8M
Volume	63,904

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -81.6M
EPS (ttm): -$31.8
Market cap: 514.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROICn/a

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All BLSM indicators

Market & fundamental data

Available fields

135

Groups with data

Currency

USD

Showing 135 of 135 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001839970
Company name	BlossomHill Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	095130100
Earnings date	2026-11-19
Earnings time	bmo
Employees	69
Enterprise value	$442.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-08-08
Fiscal year end	December
Founded	2020
Industry	Biotechnology
IPO date	2026-08-07
Is primary listing	Yes
Is SPAC	No
ISIN number	US0951301003
Last earnings date	2026-09-18
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$514.6M
Market cap category	Small-Cap
Next earnings date	2026-11-19
Options	No
Price	$16.19
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	BLSM
U.S. state	California
Website	https://bhtherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-196.58%
FCF / EV yield	-16.03%
FCF yield	-13.79%
P/B ratio	6.28x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.2M
ROCE	-80.79%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-83,000
Depreciation and amortization	$504,000
EBIT	$-85.2M
EBITDA	$-84.7M
EPS	$-31.83
FCF per share	$-2.24
Financing cash flow	$87.3M
Free cash flow	$-71.1M
Free cash flow minus SBC	$-72.6M
Investing cash flow	$-83,000
Net cash flow	$16.3M
Net income	$-81.6M
Operating cash flow minus SBC	$-72.5M
Operating income	$-85.2M
Stock-based compensation	$1.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-63.15
Debt / equity	0.28
Long-term assets	$23.2M
Long-term liabilities	$23.5M
Net cash (debt)	$72M
Net cash / market cap	13.98%
Net debt / equity	-0.88
Piotroski F-Score	1
Property, plant and equipment	$20.7M
Shareholders' equity	$82M
Tangible book value	$-174.8M
Tangible book value per share	$-63.15
Total assets	$124.1M
Total cash	$95.4M
Total debt	$23.4M
Total liabilities	$42.1M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$101M
Current liabilities	$18.6M
Current ratio	5.42
Net working capital	$-11.9M
Quick ratio	5.12
Working capital	$82.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	2.76%
1M price change	-18.51%
1M total return	-18.51%
1W price change	11.77%
1W total return	11.77%
20-day SMA	$16.31
50-day SMA	$19.03
52-week high	$27.99
52-week high date	2026-09-21
52-week low	$12.93
52-week low date	2026-10-19
All-time high	$27.99
All-time high date	2026-09-21
All-time low	$12.93
All-time low date	2026-10-19
Average true range (ATR)	$1.56
Average volume	148K
Beta (1Y)	0.81
Change from 52-week high	-42.16%
Change from 52-week low	25.21%
Change from all-time high	-42.5%
Change from all-time low	24.48%
Change from open	1.82%
Day's gap	0.89%
Dollar volume	$1M
High price	$16.19
Low price	$15.90
Monthly RSI	0
Open price	$15.90
Position in 52-week range	100%
Previous close	$15.76
Price vs 20-day SMA	-1.33%
Price vs 50-day SMA	-15.43%
Relative volume	0.43
Return from IPO open	2.92%
Return from IPO price	1.31%
RSI	45.77
Sharpe ratio	0.47
Sortino ratio	0.76
Volume	63.9K
Weekly RSI	0

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	17.7M
Float percentage	55.83%
Shares change (QoQ)	5.18%
Shares held by insiders	7.89%
Shares held by institutions	7.44%
Shares outstanding	31.8M
Short % of float	2.67%
Short % of shares	1.49%
Short ratio	2.1 days

Deeper analysis on BLSM

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BLSM report

Is a complete BLSM research report available?

No complete published report is available for BlossomHill Therapeutics, Inc. (BLSM) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BlossomHill Therapeutics, Inc. (BLSM)

Price

Financial snapshot

Fair-value bridge

Latest news · BLSM

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All BLSM indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BLSM

Frequently asked questions